{"id":27042,"date":"2025-07-17T09:48:28","date_gmt":"2025-07-17T02:48:28","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=27042"},"modified":"2025-07-17T09:48:28","modified_gmt":"2025-07-17T02:48:28","slug":"total-investment-of-approx-usd-7-3-million-in-malaria-and-tb-rd-projects-with-partners-including-european-vaccine-initiative-university-of-copenhagen-and-university-of-tubingen","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=27042","title":{"rendered":"Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With Partners Including European Vaccine Initiative, University of Copenhagen, and University of T\u00fcbingen"},"content":{"rendered":"

TOKYO<\/span>, July 17, 2025<\/span><\/span> \/PRNewswire\/ — The Global Health Innovative Technology (GHIT) Fund\u00a0announced today a total investment of approximately JPY 1 billion<\/span> (USD 7.3 million<\/span>1<\/sup>) in four R&D projects for the development of vaccine, drug, and diagnostics for malaria and tuberculosis (TB).2<\/sup><\/p>\n

Investment of JPY 800 million<\/span> (<\/b>USD 5.5 million<\/span><\/b>1<\/sup><\/b>) in malaria vaccine project<\/b><\/p>\n

Malaria is a serious infectious disease that affects more than 260 million people and claims approximately 600,000 lives worldwide each year. Over 90% of all malaria cases occur in Africa<\/span>, with more than 70% of those affected being children under the age of five.3<\/sup>\u00a0Malaria is transmitted to humans by mosquitoes. While prevention and treatment methods are available, the efficacy of currently available vaccines remains limited, highlighting the urgent need for the development of vaccines with higher efficacy and longer-lasting protection.<\/p>\n

To address this challenge, the GHIT Fund has decided to invest JPY 800 million<\/span> (USD 5.5 million<\/span>1<\/sup>) in a malaria vaccine development project currently in the preclinical stage. This project is being led by the European Vaccine Initiative, the Research Institute for Microbial Diseases (RIMD) at Osaka<\/span> University, the University of Copenhagen<\/span>, the University of T\u00fcbingen, Danish biotechnology company AdaptVac, Ajinomoto Co., Inc., and Nobelpharma Co., Ltd.<\/p>\n

This investment is a continuation of previous projects supported by GHIT, which has invested a total of approximately JPY 630 million<\/span> (USD 4.3 million<\/span>1<\/sup>) from 2013 to 2022. The present project aims to develop a vaccine that prevents the proliferation of malaria parasites during the blood-stage of infection. The vaccine is designed to achieve higher efficacy and longer-lasting protection with fewer doses. By reducing manufacturing costs, the project also aims to improve access to vaccines in malaria-endemic regions.<\/p>\n

In addition, the GHIT Fund will invest a total of approximately\u00a0JPY 260 million (USD 1.8 million<\/span>1<\/sup>) in the following three R&D projects:
(1) Target research project for malaria diagnostics by Ehime University and Universiti Malaysia Sabah
(2) Target research project for TB drug by the University of Auckland<\/span> and the University of Tokyo<\/span>
(3) Target research project for malaria drug by Medicines for Malaria Venture (MMV), LPIXEL Inc., and University of Dundee<\/span><\/p>\n

This investment brings four new companies and universities on board. Through collaborations with 190 partners across 39 countries \u2014 including 64 Japanese and 126 non-Japanese institutions \u2014 we aim to contribute to solving global health challenges and accelerating product development.<\/p>\n

Please refer to Appendix 1 for detailed descriptions on these projects and their development stages.<\/p>\n

As of July 17, 2025<\/span>, the GHIT Fund has invested in 37 projects, including 15 discovery projects, 13 preclinical projects, and 9 clinical trials.4<\/sup>\u00a0The total amount of investments since 2013 is JPY 39.3 billion<\/span> (USD 271 million<\/span>1<\/sup>) (Appendix 2).<\/p>\n

1<\/sup> USD1<\/span> = JPY144.81<\/span>, the approximate exchange rate on June 30, 2025<\/span>.
2<\/sup> These awarded projects were selected and approved as new investments from among proposals to RFP2023-002\u00a0and RFP2024-001\u00a0for the Product Development Platform\u00a0and the Target Research Platform, which were open for applications from June\u00a02023\u00a0to July 2024<\/span>.
3<\/sup>\u00a0WHO: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/malaria<\/a>
4<\/sup>\u00a0This number includes projects in the registration phase.<\/p>\n

The GHIT Fund is a Japan<\/span>-based international public-private partnership (PPP) fund that was formed between the Government of Japan<\/span>, multiple pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world’s vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases.
https:\/\/www.ghitfund.org\/en<\/a><\/p>\n

Appendix 1. Project Details\u00a0\u00a0\u00a0\u00a0<\/p>\n

ID:\u00a0G2024-201<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n
\n

Project Title<\/b><\/span><\/p>\n<\/td>\n

\n

Biomanufacture and preclinical development of the blood-stage malaria vaccine
candidate SE36\/cVLP<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Collaboration<\/b><\/span><\/p>\n

Partners<\/b><\/span><\/p>\n<\/td>\n

\n

1. European Vaccine Initiative (Germany)<\/span><\/p>\n

2. RIMD, Osaka University (Japan)<\/span><\/p>\n

3. University of Copenhagen (Denmark)<\/span><\/p>\n

4. AdaptVac (Denmark)<\/span><\/p>\n

5. University of T\u00fcbingen (Germany)<\/span><\/p>\n

6. Ajinomoto Co., Inc. (Japan)<\/span><\/p>\n

7. Nobelpharma Co., Ltd. (Japan)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Disease<\/b><\/span><\/p>\n<\/td>\n

\n

Malaria<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Intervention<\/b><\/span><\/p>\n<\/td>\n

\n

Vaccine<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Stage<\/b><\/span><\/p>\n<\/td>\n

\n

Preclinical<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Awarded Amount<\/b><\/span><\/p>\n<\/td>\n

\n

JPY 800,715,002 (USD 5.5 million)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Status<\/b><\/span><\/p>\n<\/td>\n

\n

Continued project<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Summary<\/b><\/span><\/p>\n<\/td>\n

\n

[Project objective]<\/span><\/p>\n

This team’s goal is to fast-track the clinical development of the SE36\/cVLP vaccine
candidate and obtain supporting evidence for a safe and efficacious blood-stage
vaccine that could be deployed as a stand-alone or potentially combined in a second-
generation multi-stage malaria vaccine. The main objectives are to:<\/span><\/p>\n

1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Manufacture a large GMP batch of SE36 <\/span><\/p>\n

2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Produce a GMP batch of SE36\/cVLP <\/span><\/p>\n

3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Conduct a GLP-compliant nonclinical toxicology study for SE36\/cVLP + Sepivac
\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 SWE adjuvant<\/span><\/p>\n

4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Prepare clinical trial documentation for the conduct of a phase I\/IIa (CHMI) trial
\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 for SE36\/cVLP (+\/- Sepivac SWE) to assess safety, immunogenicity, and time-to-
\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 first episode of clinical malaria in malaria-na\u00efve vaccinated subjects<\/span><\/p>\n


[Project design]
The previous GMP manufacturing process for SE36 was largely based on the E. coli<\/i>
expression system with modest yield after several chromatography steps. Benefiting
from recent collaborations and new adaptive vaccine technologies, the project team
now proposes to manufacture a larger batch of SE36 using a simplified, high-yield
process with Corynex\u2122, which utilizes Corynebacterium glutamicum<\/i>. Moreover, to
increase the vaccine immunogenicity, SE36 antigens will be displayed on capsid
virus-like particles (cVLP) ensuring unidirectional and high-density display. A
previously manufactured small lab-scale batch of SE36\/cVLP showed that coupling
was stable and that coupled SE36 was highly immunogenic in the mouse model.
Armed with this success, the project team now expands its efforts to manufacture a
larger GMP batch of SE36\/cVLP, conduct a GLP-compliant nonclinical toxicology
study and prepare trial documentation to conduct a phase I\/IIa trial with this newly
optimised formulation of the SE36 vaccine candidate. A successful completion of
these activities will set the stage for a first-in-human safety, immunogenicity and
efficacy trial.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Project Detail<\/b><\/span><\/p>\n<\/td>\n

\n

https:\/\/www.ghitfund.org\/investment\/portfoliodetail\/detail\/242\/en<\/a> <\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

ID:\u00a0T2024-153<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n
\n

Project Title<\/b><\/span><\/p>\n<\/td>\n

\n

ZOO-RDT: Validating a novel biomarker and associated reagents for diagnosis of
acute zoonotic malaria in southeast Asia<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Collaboration<\/b><\/span><\/p>\n

Partners<\/b><\/span><\/p>\n<\/td>\n

\n

1. Ehime University (Japan)<\/span><\/p>\n

2. Universiti Malaysia Sabah (Malaysia)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Disease<\/b><\/span><\/p>\n<\/td>\n

\n

Malaria<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Intervention<\/b><\/span><\/p>\n<\/td>\n

\n

Diagnostics<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Stage<\/b><\/span><\/p>\n<\/td>\n

\n

Target Research<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Awarded Amount<\/b><\/span><\/p>\n<\/td>\n

\n

JPY 64,693,198 (USD 0.4 million)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Status<\/b><\/span><\/p>\n<\/td>\n

\n

New project<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Summary<\/b><\/span><\/p>\n<\/td>\n

\n

[Project objective]<\/span><\/p>\n

There are no P. knowlesi<\/i>-specific point-of-care (PoC) tests. Rapid diagnostic tests
based on the pLDH biomarker show high cross-reactivity between P. vivax <\/i>and P.
knowlesi<\/i> making them impossible to distinguish. Current diagnostic practices take
time and delay patient access to treatment. Simple, accessible PoC tools are urgently
required. Identification of P. knowlesi-<\/i>specific diagnostic markers has been largely
neglected. The serine repeat antigen (sera) multigene family has been extensively
studied in P. falciparum<\/i> and rodent parasite lines and plays critical roles across the
parasite life cycle. The P. knowlesi<\/i> Serine Repeat Antigen 3 (PkSERA3) antigen 2
has been identified as a P. knowlesi<\/i>-specific exposure marker, with laboratory and
population-level evaluations showing no cross-reactivity with P. vivax<\/i>, a
phylogenetically closely related species. The project team will use this antigen to
develop reagents for a P. knowlesi<\/i> PoC diagnostic test.<\/span><\/p>\n


[Project design]
Overall aim<\/b>: Validate novel biomarker(s) and associated monoclonal antibodies for
lateral flow assay development for the diagnosis of acute infections.\u00a0 <\/span><\/p>\n

Objective 1<\/b>: Reagent optimisation: the optimised PkSERA3 ag 2 protein plus two
variants will be used in the generation of monoclonal antibodies (mAbs).\u00a0 <\/span><\/p>\n

Objective 2<\/b>: Analytical and clinical validation of PkSERA3 Ag2 and variants as
species-specific indicators of acute P. knowlesi<\/i> infection across epidemiological
zones.\u00a0 <\/span><\/p>\n

Objective 3<\/b>: Assessment of Technical Feasibility in the lateral flow system. The best
performing mAbs will be assayed by ELISA, and further down-selection will lead to
selected mAbs being printed onto test strips. Antibody reagents will be provided to a
diagnostic test developer Contract Research Organization (CRO) to validate the
technical feasibility of integrating the developed mAbs into a lateral-flow RDT. <\/span><\/p>\n

Objective 4<\/b>: Stakeholder consultation to understand the preferred test design, and to
inform Product Design and generate evidence for a business case for this novel
malaria RDT. <\/span><\/p>\n

Target results:<\/b> Validated P. knowlesi<\/i>-specific mAb reagent for use in LFA
development.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Project Detail<\/b><\/span><\/p>\n<\/td>\n

\n

https:\/\/www.ghitfund.org\/investment\/portfoliodetail\/detail\/243\/en<\/a> <\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

ID:\u00a0T2024-253<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n
\n

Project Title<\/b><\/span><\/p>\n<\/td>\n

\n

Harnessing genome mining for novel tuberculosis antibiotics<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Collaboration<\/b><\/span><\/p>\n

Partners<\/b><\/span><\/p>\n<\/td>\n

\n

1. The University of Auckland (New Zealand)<\/span><\/p>\n

2. The University of Tokyo (Japan)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Disease<\/b><\/span><\/p>\n<\/td>\n

\n

Tuberculosis<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Intervention<\/b><\/span><\/p>\n<\/td>\n

\n

Drug<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Stage<\/b><\/span><\/p>\n<\/td>\n

\n

Target Research<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Awarded Amount<\/b><\/span><\/p>\n<\/td>\n

\n

JPY 100,000,000 (USD 0.6 million)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Status<\/b><\/span><\/p>\n<\/td>\n

\n

New project<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Summary<\/b><\/span><\/p>\n<\/td>\n

\n

[Project objective]<\/span><\/p>\n

In the short term, this project aims to enhance TB antibiotic discovery by identifying
secondary metabolites that specifically target essential metabolic pathways in M.
tuberculosis<\/i>. By focusing on mechanisms absent in mammalian cells, the project
team aims to identify secondary metabolites with selective antimicrobial activity and
minimal side effects in humans. This selectivity is expected to improve patient
experience, compliance, and treatment outcomes. Early identification and testing of
these compounds against purified proteins, M. tuberculosis<\/i> cells, and human
macrophage infection models will provide critical insights into their efficacy and
potential as new therapeutic agents. <\/span><\/p>\n

In the long term, this project team’s goal is to translate these research findings into
clinical applications, offering new treatment options for TB patients worldwide. A
key strength of this proposal is this project team’s established expertise and drug
development pipeline, specifically in the TB context, which will be instrumental in
advancing subsequent research and development phases.<\/span><\/p>\n


[Project design]
Despite significant advances in understanding the metabolic features essential for M.
tuberculosis<\/i>, developing new antibiotics remains a major challenge. Enzyme
inhibitors often exhibit limited activity against M. tuberculosis<\/i>, and many bioactive
compounds have unclear modes of action. To overcome these challenges, the project
team will (a) identify secondary metabolites that specifically target key metabolic
pathways in M. tuberculosis<\/i>, and (b) test these metabolites against purified proteins
and M. tuberculosis<\/i> cells to assess their effects on bacterial growth and pathogenesis.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Project Detail<\/b><\/span><\/p>\n<\/td>\n

\n

https:\/\/www.ghitfund.org\/investment\/portfoliodetail\/detail\/244\/en<\/a> <\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

ID:\u00a0T2024-268<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n
\n

Project Title<\/b><\/span><\/p>\n<\/td>\n

\n

Machine learning-based deconvolution of antimalarial drug mechanisms of action
through cell painting of compound-treated Plasmodium falciparum<\/i>-infected
erythrocytes<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Collaboration<\/b><\/span><\/p>\n

Partners<\/b><\/span><\/p>\n<\/td>\n

\n

1. Medicines for Malaria Venture (MMV) (Switzerland)<\/span><\/p>\n

2. LPIXEL Inc. (Japan)<\/span><\/p>\n

3. University of Dundee (UK)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Disease<\/b><\/span><\/p>\n<\/td>\n

\n

Malaria<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Intervention<\/b><\/span><\/p>\n<\/td>\n

\n

Drug<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Stage<\/b><\/span><\/p>\n<\/td>\n

\n

Target Research<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Awarded Amount<\/b><\/span><\/p>\n<\/td>\n

\n

JPY 99,628,772 (USD 0.6 million)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Status<\/b><\/span><\/p>\n<\/td>\n

\n

New project<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Summary<\/b><\/span><\/p>\n<\/td>\n

\n

[Project objective]<\/span><\/p>\n

The project ultimately aims to deliver a new high-throughput and information-rich
platform for informing and classifying antimalarial modes of action (MoA) and
highlighting novel compound-induced phenotypes. This proposal seeks to leverage
advances in cellular imaging and machine learning-led pattern recognition. The final
goal is to develop a robust, reproducible method to deliver information on a
compound’s biological impact (whether its MoA or pathway is novel or known) in
synchrony with the confirmation of growth inhibition and thus allow clustering on
both chemistry and biology, potentially saving months in the context of Hit
Generation.<\/span><\/p>\n


[Project design]
The project relies on high-content imaging and subsequent analysis of drug-treated
Plasmodium falciparum<\/i> parasites. The initial assay development phase will optimise
methodologies for staining, fixation, and imaging of parasite-infected red blood cells,
including both healthy untreated parasites and those treated with a pilot set of
compounds with defined MoA. This will allow preliminary development of artificial
intelligence (AI) models to classify parasite morphology across the 48 hour lifecycle,
as well as the phenotypic impact of drug-treatment. Once treatment and imaging
parameters have been optimised, data collection will be performed with an expanded
set of compounds covering a diverse range of MoA, in order to refine and validate the
development of AI models for pattern recognition. AI models will ultimately be
packaged into a cloud-based, user-friendly application so that images generated by
researchers can be analysed without specialist AI knowledge.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Project Detail<\/b><\/span><\/p>\n<\/td>\n

\n

https:\/\/www.ghitfund.org\/investment\/portfoliodetail\/detail\/245\/en<\/a> <\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

*All amounts are listed at an exchange rate of USD1<\/span> = JPY144.81<\/span>, the approximate exchange rate on June 30, 2025<\/span>.<\/p>\n

Appendix 2. Investment Overview (as of July 17, 2025<\/span>)<\/p>\n

Investments to date
<\/b>Total investments: 39.3\u00a0billion yen (USD 271\u00a0million1<\/sup>)
Total invested projects: 139 (37 active projects and 102\u00a0completed projects)<\/p>\n

To learn more about the GHIT Fund’s investments, please visit
Investment Overview: https:\/\/www.ghitfund.org\/investment\/overview\/en<\/a>
Portfolio: https:\/\/www.ghitfund.org\/investment\/portfolio\/en<\/a>
Advancing Portfolio: https:\/\/www.ghitfund.org\/investment\/advancingportfolio\/en<\/a>
Clinical Candidates: https:\/\/www.ghitfund.org\/investment\/clinicalcandidates\/en<\/a><\/p>\n

For more information, contact:
Nancy Moss<\/span> at +1-908-606-8940 or nmoss@burness.com<\/a>
Mina Ohata<\/span> at +81-36441-2032 or mina.ohata@ghitfund.org<\/a><\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

TOKYO<\/span>, July 17, 2025<\/span><\/span> \/PRNewswire\/ — The Global Health Innovative Technology (GHIT) Fund\u00a0announced today a total investment of approximately JPY 1 billion<\/span> (USD 7.3 million<\/span>1<\/sup>) in four R&D projects for the development of vaccine, drug, and diagnostics for malaria and tuberculosis (TB).2<\/sup><\/p>\n

Investment of JPY 800 million<\/span> (<\/b>USD 5.5 million<\/span><\/b>1<\/sup><\/b>) in malaria vaccine project<\/b><\/p>\n

Malaria is a serious infectious disease that affects more than 260 million people and claims approximately 600,000 lives worldwide each year. Over 90% of all malaria cases occur in Africa<\/span>, with more than 70% of those affected being children under the age of five.3<\/sup>\u00a0Malaria is transmitted to humans by mosquitoes. While prevention and treatment methods are available, the efficacy of currently available vaccines remains limited, highlighting the urgent need for the development of vaccines with higher efficacy and longer-lasting protection.<\/p>\n

To address this challenge, the GHIT Fund has decided to invest JPY 800 million<\/span> (USD 5.5 million<\/span>1<\/sup>) in a malaria vaccine development project currently in the preclinical stage. This project is being led by the European Vaccine Initiative, the Research Institute for Microbial Diseases (RIMD) at Osaka<\/span> University, the University of Copenhagen<\/span>, the University of T\u00fcbingen, Danish biotechnology company AdaptVac, Ajinomoto Co., Inc., and Nobelpharma Co., Ltd.<\/p>\n

This investment is a continuation of previous projects supported by GHIT, which has invested a total of approximately JPY 630 million<\/span> (USD 4.3 million<\/span>1<\/sup>) from 2013 to 2022. The present project aims to develop a vaccine that prevents the proliferation of malaria parasites during the blood-stage of infection. The vaccine is designed to achieve higher efficacy and longer-lasting protection with fewer doses. By reducing manufacturing costs, the project also aims to improve access to vaccines in malaria-endemic regions.<\/p>\n

In addition, the GHIT Fund will invest a total of approximately\u00a0JPY 260 million (USD 1.8 million<\/span>1<\/sup>) in the following three R&D projects:
(1) Target research project for malaria diagnostics by Ehime University and Universiti Malaysia Sabah
(2) Target research project for TB drug by the University of Auckland<\/span> and the University of Tokyo<\/span>
(3) Target research project for malaria drug by Medicines for Malaria Venture (MMV), LPIXEL Inc., and University of Dundee<\/span><\/p>\n

This investment brings four new companies and universities on board. Through collaborations with 190 partners across 39 countries \u2014 including 64 Japanese and 126 non-Japanese institutions \u2014 we aim to contribute to solving global health challenges and accelerating product development.<\/p>\n

Please refer to Appendix 1 for detailed descriptions on these projects and their development stages.<\/p>\n

As of July 17, 2025<\/span>, the GHIT Fund has invested in 37 projects, including 15 discovery projects, 13 preclinical projects, and 9 clinical trials.4<\/sup>\u00a0The total amount of investments since 2013 is JPY 39.3 billion<\/span> (USD 271 million<\/span>1<\/sup>) (Appendix 2).<\/p>\n

1<\/sup> USD1<\/span> = JPY144.81<\/span>, the approximate exchange rate on June 30, 2025<\/span>.
2<\/sup> These awarded projects were selected and approved as new investments from among proposals to RFP2023-002\u00a0and RFP2024-001\u00a0for the Product Development Platform\u00a0and the Target Research Platform, which were open for applications from June\u00a02023\u00a0to July 2024<\/span>.
3<\/sup>\u00a0WHO: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/malaria<\/a>
4<\/sup>\u00a0This number includes projects in the registration phase.<\/p>\n

The GHIT Fund is a Japan<\/span>-based international public-private partnership (PPP) fund that was formed between the Government of Japan<\/span>, multiple pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world’s vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases.
https:\/\/www.ghitfund.org\/en<\/a><\/p>\n

Appendix 1. Project Details\u00a0\u00a0\u00a0\u00a0<\/p>\n

ID:\u00a0G2024-201<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n
\n

Project Title<\/b><\/span><\/p>\n<\/td>\n

\n

Biomanufacture and preclinical development of the blood-stage malaria vaccine
candidate SE36\/cVLP<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Collaboration<\/b><\/span><\/p>\n

Partners<\/b><\/span><\/p>\n<\/td>\n

\n

1. European Vaccine Initiative (Germany)<\/span><\/p>\n

2. RIMD, Osaka University (Japan)<\/span><\/p>\n

3. University of Copenhagen (Denmark)<\/span><\/p>\n

4. AdaptVac (Denmark)<\/span><\/p>\n

5. University of T\u00fcbingen (Germany)<\/span><\/p>\n

6. Ajinomoto Co., Inc. (Japan)<\/span><\/p>\n

7. Nobelpharma Co., Ltd. (Japan)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Disease<\/b><\/span><\/p>\n<\/td>\n

\n

Malaria<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Intervention<\/b><\/span><\/p>\n<\/td>\n

\n

Vaccine<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Stage<\/b><\/span><\/p>\n<\/td>\n

\n

Preclinical<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Awarded Amount<\/b><\/span><\/p>\n<\/td>\n

\n

JPY 800,715,002 (USD 5.5 million)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Status<\/b><\/span><\/p>\n<\/td>\n

\n

Continued project<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Summary<\/b><\/span><\/p>\n<\/td>\n

\n

[Project objective]<\/span><\/p>\n

This team’s goal is to fast-track the clinical development of the SE36\/cVLP vaccine
candidate and obtain supporting evidence for a safe and efficacious blood-stage
vaccine that could be deployed as a stand-alone or potentially combined in a second-
generation multi-stage malaria vaccine. The main objectives are to:<\/span><\/p>\n

1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Manufacture a large GMP batch of SE36 <\/span><\/p>\n

2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Produce a GMP batch of SE36\/cVLP <\/span><\/p>\n

3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Conduct a GLP-compliant nonclinical toxicology study for SE36\/cVLP + Sepivac
\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 SWE adjuvant<\/span><\/p>\n

4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Prepare clinical trial documentation for the conduct of a phase I\/IIa (CHMI) trial
\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 for SE36\/cVLP (+\/- Sepivac SWE) to assess safety, immunogenicity, and time-to-
\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 first episode of clinical malaria in malaria-na\u00efve vaccinated subjects<\/span><\/p>\n


[Project design]
The previous GMP manufacturing process for SE36 was largely based on the E. coli<\/i>
expression system with modest yield after several chromatography steps. Benefiting
from recent collaborations and new adaptive vaccine technologies, the project team
now proposes to manufacture a larger batch of SE36 using a simplified, high-yield
process with Corynex\u2122, which utilizes Corynebacterium glutamicum<\/i>. Moreover, to
increase the vaccine immunogenicity, SE36 antigens will be displayed on capsid
virus-like particles (cVLP) ensuring unidirectional and high-density display. A
previously manufactured small lab-scale batch of SE36\/cVLP showed that coupling
was stable and that coupled SE36 was highly immunogenic in the mouse model.
Armed with this success, the project team now expands its efforts to manufacture a
larger GMP batch of SE36\/cVLP, conduct a GLP-compliant nonclinical toxicology
study and prepare trial documentation to conduct a phase I\/IIa trial with this newly
optimised formulation of the SE36 vaccine candidate. A successful completion of
these activities will set the stage for a first-in-human safety, immunogenicity and
efficacy trial.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Project Detail<\/b><\/span><\/p>\n<\/td>\n

\n

https:\/\/www.ghitfund.org\/investment\/portfoliodetail\/detail\/242\/en<\/a> <\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

ID:\u00a0T2024-153<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n
\n

Project Title<\/b><\/span><\/p>\n<\/td>\n

\n

ZOO-RDT: Validating a novel biomarker and associated reagents for diagnosis of
acute zoonotic malaria in southeast Asia<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Collaboration<\/b><\/span><\/p>\n

Partners<\/b><\/span><\/p>\n<\/td>\n

\n

1. Ehime University (Japan)<\/span><\/p>\n

2. Universiti Malaysia Sabah (Malaysia)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Disease<\/b><\/span><\/p>\n<\/td>\n

\n

Malaria<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Intervention<\/b><\/span><\/p>\n<\/td>\n

\n

Diagnostics<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Stage<\/b><\/span><\/p>\n<\/td>\n

\n

Target Research<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Awarded Amount<\/b><\/span><\/p>\n<\/td>\n

\n

JPY 64,693,198 (USD 0.4 million)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Status<\/b><\/span><\/p>\n<\/td>\n

\n

New project<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Summary<\/b><\/span><\/p>\n<\/td>\n

\n

[Project objective]<\/span><\/p>\n

There are no P. knowlesi<\/i>-specific point-of-care (PoC) tests. Rapid diagnostic tests
based on the pLDH biomarker show high cross-reactivity between P. vivax <\/i>and P.
knowlesi<\/i> making them impossible to distinguish. Current diagnostic practices take
time and delay patient access to treatment. Simple, accessible PoC tools are urgently
required. Identification of P. knowlesi-<\/i>specific diagnostic markers has been largely
neglected. The serine repeat antigen (sera) multigene family has been extensively
studied in P. falciparum<\/i> and rodent parasite lines and plays critical roles across the
parasite life cycle. The P. knowlesi<\/i> Serine Repeat Antigen 3 (PkSERA3) antigen 2
has been identified as a P. knowlesi<\/i>-specific exposure marker, with laboratory and
population-level evaluations showing no cross-reactivity with P. vivax<\/i>, a
phylogenetically closely related species. The project team will use this antigen to
develop reagents for a P. knowlesi<\/i> PoC diagnostic test.<\/span><\/p>\n


[Project design]
Overall aim<\/b>: Validate novel biomarker(s) and associated monoclonal antibodies for
lateral flow assay development for the diagnosis of acute infections.\u00a0 <\/span><\/p>\n

Objective 1<\/b>: Reagent optimisation: the optimised PkSERA3 ag 2 protein plus two
variants will be used in the generation of monoclonal antibodies (mAbs).\u00a0 <\/span><\/p>\n

Objective 2<\/b>: Analytical and clinical validation of PkSERA3 Ag2 and variants as
species-specific indicators of acute P. knowlesi<\/i> infection across epidemiological
zones.\u00a0 <\/span><\/p>\n

Objective 3<\/b>: Assessment of Technical Feasibility in the lateral flow system. The best
performing mAbs will be assayed by ELISA, and further down-selection will lead to
selected mAbs being printed onto test strips. Antibody reagents will be provided to a
diagnostic test developer Contract Research Organization (CRO) to validate the
technical feasibility of integrating the developed mAbs into a lateral-flow RDT. <\/span><\/p>\n

Objective 4<\/b>: Stakeholder consultation to understand the preferred test design, and to
inform Product Design and generate evidence for a business case for this novel
malaria RDT. <\/span><\/p>\n

Target results:<\/b> Validated P. knowlesi<\/i>-specific mAb reagent for use in LFA
development.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Project Detail<\/b><\/span><\/p>\n<\/td>\n

\n

https:\/\/www.ghitfund.org\/investment\/portfoliodetail\/detail\/243\/en<\/a> <\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

ID:\u00a0T2024-253<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n
\n

Project Title<\/b><\/span><\/p>\n<\/td>\n

\n

Harnessing genome mining for novel tuberculosis antibiotics<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Collaboration<\/b><\/span><\/p>\n

Partners<\/b><\/span><\/p>\n<\/td>\n

\n

1. The University of Auckland (New Zealand)<\/span><\/p>\n

2. The University of Tokyo (Japan)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Disease<\/b><\/span><\/p>\n<\/td>\n

\n

Tuberculosis<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Intervention<\/b><\/span><\/p>\n<\/td>\n

\n

Drug<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Stage<\/b><\/span><\/p>\n<\/td>\n

\n

Target Research<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Awarded Amount<\/b><\/span><\/p>\n<\/td>\n

\n

JPY 100,000,000 (USD 0.6 million)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Status<\/b><\/span><\/p>\n<\/td>\n

\n

New project<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Summary<\/b><\/span><\/p>\n<\/td>\n

\n

[Project objective]<\/span><\/p>\n

In the short term, this project aims to enhance TB antibiotic discovery by identifying
secondary metabolites that specifically target essential metabolic pathways in M.
tuberculosis<\/i>. By focusing on mechanisms absent in mammalian cells, the project
team aims to identify secondary metabolites with selective antimicrobial activity and
minimal side effects in humans. This selectivity is expected to improve patient
experience, compliance, and treatment outcomes. Early identification and testing of
these compounds against purified proteins, M. tuberculosis<\/i> cells, and human
macrophage infection models will provide critical insights into their efficacy and
potential as new therapeutic agents. <\/span><\/p>\n

In the long term, this project team’s goal is to translate these research findings into
clinical applications, offering new treatment options for TB patients worldwide. A
key strength of this proposal is this project team’s established expertise and drug
development pipeline, specifically in the TB context, which will be instrumental in
advancing subsequent research and development phases.<\/span><\/p>\n


[Project design]
Despite significant advances in understanding the metabolic features essential for M.
tuberculosis<\/i>, developing new antibiotics remains a major challenge. Enzyme
inhibitors often exhibit limited activity against M. tuberculosis<\/i>, and many bioactive
compounds have unclear modes of action. To overcome these challenges, the project
team will (a) identify secondary metabolites that specifically target key metabolic
pathways in M. tuberculosis<\/i>, and (b) test these metabolites against purified proteins
and M. tuberculosis<\/i> cells to assess their effects on bacterial growth and pathogenesis.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Project Detail<\/b><\/span><\/p>\n<\/td>\n

\n

https:\/\/www.ghitfund.org\/investment\/portfoliodetail\/detail\/244\/en<\/a> <\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

ID:\u00a0T2024-268<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n
\n

Project Title<\/b><\/span><\/p>\n<\/td>\n

\n

Machine learning-based deconvolution of antimalarial drug mechanisms of action
through cell painting of compound-treated Plasmodium falciparum<\/i>-infected
erythrocytes<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Collaboration<\/b><\/span><\/p>\n

Partners<\/b><\/span><\/p>\n<\/td>\n

\n

1. Medicines for Malaria Venture (MMV) (Switzerland)<\/span><\/p>\n

2. LPIXEL Inc. (Japan)<\/span><\/p>\n

3. University of Dundee (UK)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Disease<\/b><\/span><\/p>\n<\/td>\n

\n

Malaria<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Intervention<\/b><\/span><\/p>\n<\/td>\n

\n

Drug<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Stage<\/b><\/span><\/p>\n<\/td>\n

\n

Target Research<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Awarded Amount<\/b><\/span><\/p>\n<\/td>\n

\n

JPY 99,628,772 (USD 0.6 million)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Status<\/b><\/span><\/p>\n<\/td>\n

\n

New project<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Summary<\/b><\/span><\/p>\n<\/td>\n

\n

[Project objective]<\/span><\/p>\n

The project ultimately aims to deliver a new high-throughput and information-rich
platform for informing and classifying antimalarial modes of action (MoA) and
highlighting novel compound-induced phenotypes. This proposal seeks to leverage
advances in cellular imaging and machine learning-led pattern recognition. The final
goal is to develop a robust, reproducible method to deliver information on a
compound’s biological impact (whether its MoA or pathway is novel or known) in
synchrony with the confirmation of growth inhibition and thus allow clustering on
both chemistry and biology, potentially saving months in the context of Hit
Generation.<\/span><\/p>\n


[Project design]
The project relies on high-content imaging and subsequent analysis of drug-treated
Plasmodium falciparum<\/i> parasites. The initial assay development phase will optimise
methodologies for staining, fixation, and imaging of parasite-infected red blood cells,
including both healthy untreated parasites and those treated with a pilot set of
compounds with defined MoA. This will allow preliminary development of artificial
intelligence (AI) models to classify parasite morphology across the 48 hour lifecycle,
as well as the phenotypic impact of drug-treatment. Once treatment and imaging
parameters have been optimised, data collection will be performed with an expanded
set of compounds covering a diverse range of MoA, in order to refine and validate the
development of AI models for pattern recognition. AI models will ultimately be
packaged into a cloud-based, user-friendly application so that images generated by
researchers can be analysed without specialist AI knowledge.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Project Detail<\/b><\/span><\/p>\n<\/td>\n

\n

https:\/\/www.ghitfund.org\/investment\/portfoliodetail\/detail\/245\/en<\/a> <\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

*All amounts are listed at an exchange rate of USD1<\/span> = JPY144.81<\/span>, the approximate exchange rate on June 30, 2025<\/span>.<\/p>\n

Appendix 2. Investment Overview (as of July 17, 2025<\/span>)<\/p>\n

Investments to date
<\/b>Total investments: 39.3\u00a0billion yen (USD 271\u00a0million1<\/sup>)
Total invested projects: 139 (37 active projects and 102\u00a0completed projects)<\/p>\n

To learn more about the GHIT Fund’s investments, please visit
Investment Overview: https:\/\/www.ghitfund.org\/investment\/overview\/en<\/a>
Portfolio: https:\/\/www.ghitfund.org\/investment\/portfolio\/en<\/a>
Advancing Portfolio: https:\/\/www.ghitfund.org\/investment\/advancingportfolio\/en<\/a>
Clinical Candidates: https:\/\/www.ghitfund.org\/investment\/clinicalcandidates\/en<\/a><\/p>\n

For more information, contact:
Nancy Moss<\/span> at +1-908-606-8940 or nmoss@burness.com<\/a>
Mina Ohata<\/span> at +81-36441-2032 or mina.ohata@ghitfund.org<\/a><\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-27042","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/27042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=27042"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/27042\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=27042"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=27042"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=27042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}